scispace - formally typeset
Y

Yongjun Jiao

Researcher at Chinese Center for Disease Control and Prevention

Publications -  22
Citations -  1002

Yongjun Jiao is an academic researcher from Chinese Center for Disease Control and Prevention. The author has contributed to research in topics: Virus & Severe fever with thrombocytopenia syndrome virus. The author has an hindex of 11, co-authored 22 publications receiving 785 citations. Previous affiliations of Yongjun Jiao include Centers for Disease Control and Prevention.

Papers
More filters
Journal ArticleDOI

Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China.

TL;DR: It is suggested that combinatorial analysis of serum cytokines and chemokines with clinical classification may contribute to evaluation of the severity of COVID-19 and optimize the therapeutic strategies.
Journal ArticleDOI

Preparation and Evaluation of Recombinant Severe Fever with Thrombocytopenia Syndrome Virus Nucleocapsid Protein for Detection of Total Antibodies in Human and Animal Sera by Double-Antigen Sandwich Enzyme-Linked Immunosorbent Assay

TL;DR: The cloning and expression of the nucleocapsid (N) protein of SFTSV is described, and this assay, which is simple to operate, poses no biohazard risk, does not require sophisticated equipment, and can be used in disease surveillance programs, particularly in the screening of large numbers of samples from various animal species.
Journal ArticleDOI

Cytokine and Chemokine Levels in Patients Infected With the Novel Avian Influenza A (H7N9) Virus in China

TL;DR: It is suggested that proinflammatory cytokine responses, characterized by a combined Th1/Th17 cytokine induction, are partially responsible for the disease progression of patients with H7N9 infection.
Journal ArticleDOI

Human Antibody Neutralizes Severe Fever with Thrombocytopenia Syndrome Virus, an Emerging Hemorrhagic Fever Virus

TL;DR: A combinatorial human antibody library constructed from the peripheral lymphocytes of 5 patients who had recovered from SFTS suggests that MAb 4-5 can be used as a promising candidate molecule for immunotherapy against SFTSV infection.